TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial

Journal:
The Lancet Oncology
Published:
DOI:
10.1016/s1470-2045(25)00358-4
Affiliations:
21
Authors:
19
Go to article
Institutions Authors Share
Johnson & Johnson, United States of America (USA)
3.000000
 0.16
Seoul National University Hospital (SNUH), South Korea
1.000000
 0.05
START Carolinas, United States of America (USA)
1.000000
 0.05
Clinique La Croix du Sud, France
1.000000
 0.05
University Hospital of Münster (UKM), WWU, Germany
1.000000
 0.05
University of Florida (UF), United States of America (USA)
1.000000
 0.05
Bichat-Claude Bernard Hospital, France
1.000000
 0.05
Institute of Biomedical Research in Malaga (IBIMA), Spain
1.000000
 0.05
Johnson & Johnson Consumer France SAS, France
1.000000
 0.05
Miami Cancer Institute, United States of America (USA)
1.000000
 0.05
Hospital Universitario 12 de Octubre, Spain
1.000000
 0.05
The University of Alabama at Birmingham (UAB), United States of America (USA)
1.000000
 0.05
Johnson & Johnson, Spain, Spain
1.000000
 0.05
Barts Health NHS Trust, United Kingdom (UK)
0.500000
 0.03
Brigham and Women's Hospital (BWH), United States of America (USA)
0.500000
 0.03
Dana-Farber Cancer Institute (DFCI), United States of America (USA)
0.500000
 0.03
University of Washington (UW), United States of America (USA)
0.500000
 0.03
Fred Hutchinson Cancer Center, United States of America (USA)
0.500000
 0.03
IRCCS San Raffaele Hospital (HSR), Italy
0.500000
 0.03
Vita-Salute San Raffaele University (UniSR), Italy
0.500000
 0.03
Royal Free London NHS Foundation Trust, United Kingdom (UK)
0.500000
 0.03
Interested in Oncology and Carcinogenesis?